XML 29 R21.htm IDEA: XBRL DOCUMENT
v3.25.3

Net Loss Per Share | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Net Loss Per Share | 10. Net Loss Per Share The Company’s basic and diluted net loss per share is calculated by dividing net loss less any redemption or induced conversion on the Series B Preferred Stock by the weighted-average number of shares of common stock outstanding for the period. RSUs, performance stock units (“PSUs”), options to purchase the Company’s common stock, restricted stock, Employee Stock Purchase Plan (“ESPP”) shares pending issuance, Series B Preferred Stock and convertible notes are considered to be potentially dilutive common shares but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. On January 23, 2022, the Company entered into separate Series B Convertible Preferred Stock Purchase Agreements (collectively, the “Purchase Agreements”) with Casdin Private Growth Equity Fund II, L.P. and Casdin Partners Master Fund, L.P. (together, “Casdin”), and Viking Global Opportunities Illiquid Investments Sub Master LP and Viking Global Opportunities Drawdown LP (together, Viking, and collectively with Casdin, the “Investors”), whereby the Company issued and sold an aggregate of $225.0 million of convertible preferred stock, consisting of: (i) 112,500 shares of the Company’s Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “Series B-1 Preferred Stock”), at a purchase price of $1,000 per share; and (ii) 112,500 shares of the Company’s Series B-2 Convertible Preferred Stock, par value $0.001 per share (the “Series B-2 Preferred Stock”, and together with the Series B-1 Preferred Stock, the “Series B Preferred Stock”) at a purchase price of $1,000 per share. On March 18, 2024, the Company entered into an exchange agreement (the “Exchange Agreement”) with the Investors in which all outstanding shares of Series B Preferred Stock were exchanged for an aggregate of 92,930,553 shares of the Company's common stock. This transaction was determined to be an induced conversion due to a reduction in the original conversion price. The excess of the fair value of the common stock issued over the fair value of shares issuable under original terms represents an in-substance distribution to the Investors, and was included as a reduction to the numerator in calculating earnings per share for the three and nine months ended September 30, 2024. Computation of net loss per share for the three and nine months ended September 30, 2025 and 2024 was as follows (in thousands, except per share data):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Numerator: |  |  |  |  |  |  |  |  |  |  |  |
Net loss from continuing operations |  | $ | (31,684 | ) |  | $ | (21,919 | ) |  | $ | (72,727 | ) |  | $ | (63,766 | )
Less: Induced conversion of redeemable preferred stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (46,014 | )
Net loss from continuing operations attributable to common stockholders |  |  | (31,684 | ) |  |  | (21,919 | ) |  |  | (72,727 | ) |  |  | (109,780 | )
Less: Net loss from discontinued operations |  |  | (3,003 | ) |  |  | (5,019 | ) |  |  | (21,452 | ) |  |  | (41,047 | )
Net loss attributable to common stockholders |  | $ | (34,687 | ) |  | $ | (26,938 | ) |  | $ | (94,179 | ) |  | $ | (150,827 | )
Denominator: |  |  |  |  |  |  |  |  |  |  |  |
Weighted-average shares outstanding during the period |  |  | 382,630 |  |  |  | 371,538 |  |  |  | 380,468 |  |  |  | 346,093 |
Net loss per share, basic and diluted: |  |  |  |  |  |  |  |  |  |  |  |
From continuing operations |  | $ | (0.08 | ) |  | $ | (0.06 | ) |  | $ | (0.19 | ) |  | $ | (0.32 | )
From discontinued operations |  | $ | (0.01 | ) |  | $ | (0.01 | ) |  | $ | (0.06 | ) |  | $ | (0.12 | )
Attributable to common stockholders |  | $ | (0.09 | ) |  | $ | (0.07 | ) |  | $ | (0.25 | ) |  | $ | (0.44 | )
The following potentially dilutive common shares were excluded from the computations of diluted net loss per share for the periods presented because including them would have been anti-dilutive (in thousands):
|  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |
RSUs, PSUs, stock options, restricted shares and ESPP shares |  |  | 56,030 |  |  |  | 54,664 |
2019 Notes |  |  | — |  |  |  | 18,966 |
2014 Notes |  |  | 5 |  |  |  | 5 |
Warrants |  |  | 11,692 |  |  |  | 11,692 |
Total |  |  | 67,727 |  |  |  | 85,327 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration